Revolution Medicines RVMD Stock
Revolution Medicines Price Chart
Revolution Medicines RVMD Financial and Trading Overview
| Revolution Medicines stock price | 200.87 USD |
| Previous Close | 206.64 USD |
| Open | 207.68 USD |
| Bid | 190.55 USD x 200 |
| Ask | 218.95 USD x 200 |
| Day's Range | 201.84 - 210.27 USD |
| 52 Week Range | 45.8 - 224.31 USD |
| Volume | 1.42M USD |
| Avg. Volume | 1.91M USD |
| Market Cap | 44.51B USD |
| Beta (5Y Monthly) | 1.401 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.87 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 258.79 USD |
RVMD Valuation Measures
| Enterprise Value | 41.77B USD |
| Trailing P/E | N/A |
| Forward P/E | -35.61983 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 27.716534 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -25.81 |
Trading Information
Revolution Medicines Stock Price History
| Beta (5Y Monthly) | 1.401 |
| 52-Week Change | 343.62% |
| S&P500 52-Week Change | 14.57% |
| 52 Week High | 224.31 USD |
| 52 Week Low | 45.8 USD |
| 50-Day Moving Average | 202.39 USD |
| 200-Day Moving Average | 145.93 USD |
RVMD Share Statistics
| Avg. Volume (3 month) | 1.91M USD |
| Avg. Daily Volume (10-Days) | 2.15M USD |
| Shares Outstanding | 214.34M |
| Float | 184.61M |
| Short Ratio | 5.53 |
| % Held by Insiders | 1.85% |
| % Held by Institutions | 100.98% |
| Shares Short | 9.67M |
| Short % of Float | 4.76% |
| Short % of Shares Outstanding | 4.51% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.12% |
| Return on Equity (ttm) | -79.088% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -1296338048 USD |
| EBITDA | -1618188032 USD |
| Net Income Avi to Common (ttm) | -1768285056 USD |
| Diluted EPS (ttm) | -8.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.94B USD |
| Total Cash Per Share (mrq) | 18.37 USD |
| Total Debt (mrq) | 1.19B USD |
| Total Debt/Equity (mrq) | 45.68 USD |
| Current Ratio (mrq) | 11.378 |
| Book Value Per Share (mrq) | 7.493 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1223032960 USD |
| Levered Free Cash Flow (ttm) | -711607360 USD |
Profile of Revolution Medicines
| Country | United States |
| State | CA |
| City | Redwood City |
| Address | 700 Saginaw Drive |
| ZIP | 94063 |
| Phone | 650 481 6801 |
| Website | https://www.revmed.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 883 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Q&A For Revolution Medicines Stock
What is a current RVMD stock price?
Revolution Medicines RVMD stock price today per share is 200.87 USD.
How to purchase Revolution Medicines stock?
You can buy RVMD shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Revolution Medicines?
The stock symbol or ticker of Revolution Medicines is RVMD.
Which industry does the Revolution Medicines company belong to?
The Revolution Medicines industry is Biotechnology.
How many shares does Revolution Medicines have in circulation?
The max supply of Revolution Medicines shares is 214.34M.
What is Revolution Medicines Price to Earnings Ratio (PE Ratio)?
Revolution Medicines PE Ratio is now.
What was Revolution Medicines earnings per share over the trailing 12 months (TTM)?
Revolution Medicines EPS is -8.87 USD over the trailing 12 months.
Which sector does the Revolution Medicines company belong to?
The Revolution Medicines sector is Healthcare.
Revolution Medicines RVMD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27538.69 USD — |
-0.22
|
6.46B USD — | 27341.31 USD — | 27547.2 USD — | — - | 6.46B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13561.68 USD — |
-0.2
|
— — | 13462.5 USD — | 13565.81 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
2985.95 USD — |
-1.32
|
— — | 2979.64 USD — | 2998.64 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
3916.11 USD — |
-1.47
|
— — | 3903.76 USD — | 3927.71 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6879.32 USD — |
+0.28
|
— — | 6808.22 USD — | 6956.93 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1295.78 USD — |
+0.26
|
— — | 1284.67 USD — | 1308.07 USD — | — - | — — |
- {{ link.label }} {{link}}
